In this week’s edition of InnovationRx, we look at the Haitian immigrant who built a $6 billion company treating brain diseases, the drugs RFK Jr. may target after Tylenol, Northwell’s new CEO, and more.| Amy Feldman
In this week’s edition of InnovationRx, we look at a startup working to fix drug pricing, Pfizer’s obesity bet and more.| InnovationRx
In this week’s edition of InnovationRx, we look at risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more.| Forbes
In this week’s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs from nature, Summit Therapeutics’ miss, and more.| Forbes
In this week’s edition of InnovationRx, we look at the Walgreens' new CEO, Alnylam's blood pressure treatment, and more.| InnovationRx
In this week’s edition of InnovationRx, we look at whether Congress will extend Obamacare subsidies, the latest data on Lilly’s obesity pill and more.| Forbes
In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a new treatment for fibromyalgia, and more.| InnovationRx
In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models of living cells, and more.| Forbes
In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ending drug testing on animals and more.| Amy Feldman
In this week’s edition of InnovationRx, we look at Halle Berry’s menopause startup, Ambience Healthcare’s $243 million fundraise, and more.| Forbes
In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ARCH Venture's latest biotech company, and more.| Amy Feldman
In this week’s edition of InnovationRx, we look at how Daniel Nadler became a billionaire building a ChatGPT for doctors, big news from two Chinese biotech companies, what doctors think about AI and more.| Forbes
In this week’s edition of InnovationRx, we look at the trend in fatal drug overdoses, 23andMe’s bankruptcy, the new CDC nominee, and more.| Forbes
In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over vaccine limits, venture funding for digital health, and more.| Amy Feldman
In this week’s edition of InnovationRx, we look at the health impact of the Republican spending bill, a startup that built a hospital in India to test its AI software, the impact of the vaccine panel changes, and more.| Forbes
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban bars foreign doctors, the first FDA-approved transcontinental telesurgery, and more.| Forbes
In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding of research on AI and healthcare, Omada’s IPO and more.| Forbes
In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, Medtronic’s diabetes spinoff, Regeneron’s purchase of 23AndMe, and more.| Forbes
In this week’s edition of InnovationRx, we look at Aetna’s withdrawal from the ACA exchanges, the potential for digital health consolidation, high error rates from new AI models, a radioisotope deal and more.| Forbes
In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias in clinical AI, Amgen’s AI hire from Nike, and more.| Forbes
In this week’s edition of InnovationRx, we look at the impact of tariffs on healthcare costs, pioneers of treating MS, AI for clinical decision-making, and more.| Forbes